Vertex Pharma (VRTX) Tops Q1 EPS by 14c; Reiterates Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Vertex Pharma (VRTX) Tops Q1 EPS by 14c; Reiterates Outlook

Vertex (VRTX) PT Raised to $202 at RBC Capital

April 27, 2018 9:01 AM EDT

RBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $202.00 (from $199.00) while maintaining a Outperform rating.

... More

Vertex Pharma (VRTX) Begins Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as Triple Combination Regimen for People with Cystic Fibrosis

April 26, 2018 4:37 PM EDT

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF). The first Phase 3 study will evaluate approximately 360 people with CF who have one copy of the... More